Concord Biotech Limited delivered robust financial results for the first quarter of FY27, reporting a consolidated net profit (PAT) of ₹57.7 crore, a 31% increase from ₹44.1 crore in Q1FY26. The growth was underpinned by a 26% rise in revenue from operations to ₹257.5 crore, reflecting broad-based demand across its Active Pharmaceutical Ingredients (API) and formulation segments. This performance signals strengthening market share and operational efficiency for the biopharma firm.

The company filed its unaudited standalone and consolidated financial results with the National Stock Exchange of India Limited and BSE Limited on August 01, 2026, pursuant to Regulation 30 and Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Paritosh Trivedi, Company Secretary and Compliance Officer.

Financial Performance Breakdown

Revenue growth was primarily driven by the API segment, which saw a 42% year-on-year increase to ₹218.9 crore from ₹153.8 crore in Q1FY26. In contrast, formulation revenue declined 23% to ₹38.6 crore from ₹50.2 crore. Geographically, export revenue surged 46% to ₹121.7 crore, significantly outpacing domestic revenue growth of 12% to ₹135.8 crore.

Excluding the impact of the injectable facility and expenses related to Stellon Biotech, EBITDA margins stood at 37% for Q1FY27. Cost of goods sold increased to ₹54 crore from ₹45 crore, while employee costs rose to ₹44 crore from ₹38 crore.

Operational Highlights

Ankur Vaid, Joint Managing Director & Chief Executive Officer, attributed the performance to increased wallet share among existing customers and the addition of new products. The company noted advanced discussions with large customers and a robust pipeline targeting 2-3 product launches annually. Regulatory milestones included USFDA approvals for Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil and Tofacitinib Tablets.

The company also completed inspections by ANVISA at its Limbasi facility and by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. Additionally, Concord Biotech received a Silver Medal from EcoVadis, placing it among the top 15% of companies assessed globally for sustainability.

What the Numbers Show

The divergence between API and formulation revenue highlights a strategic shift or temporary headwind in the latter segment. While API revenue surged 42%, formulation revenue contracted 23%. However, the overall margin expansion—EBITDA margins up 190 basis points—suggests that the higher-margin API mix is driving profitability despite the volume drop in formulations. The 46% export growth further indicates successful penetration into regulated international markets, reducing reliance on domestic demand.

Concord Biotech delivered a robust performance in the latest quarter, reporting a year-on-year increase across all key financial metrics. Standalone net profit climbed to 612M rupees from 425M rupees in the corresponding period of the previous year, while revenue surged to 2.6B rupees compared to 2.04B rupees year-on-year, underscoring the company's consistent growth trajectory in the biopharma segment.

Financial Performance at a Glance

The company's operational efficiency was evident in its EBITDA figures, which rose to 872M rupees from 614M rupees year-on-year. Notably, the EBITDA margin expanded meaningfully to 33.46% from 30.1% in the same period last year, indicating improved cost management and operating leverage. The table below summarises the key financial metrics for the quarter:

Profitability and Margin Expansion

The year-on-year improvement in EBITDA margin—from 30.1% to 33.46%—highlights Concord Biotech's ability to scale revenues while maintaining disciplined cost controls. The standalone net profit growth from 425M rupees to 612M rupees further reinforces the strength of the company's earnings profile during the quarter. Revenue expansion of approximately 2.6B rupees against 2.04B rupees in the prior year period reflects healthy demand dynamics across the company's product portfolio.